In a study of adults with HIV lipoatrophy, switching from stavudine or zidovudine to abacavir led to a “significant, albeit modest” improvement in objective measures of limb fat, without affecting control of HIV replication.
“This is the first study to convincingly show that lipoatrophy can be improved,” lead investigator Dr. Andrew Carr of St. Vincent’s Hospital in Sydney, Australia, told Reuters Health. “This is important as lipoatrophy is distressing to patients, potentially stigmatizing and has been significantly linked with poorer adherence to antiretroviral therapy,” he added.
Nucleoside reverse transcriptase inhibitor (NRTI)-induced mitochondrial toxicity is thought to underlie HIV lipoatrophy, Dr. Carr and colleagues explain in The Journal of the American Medical Association for July 10th, noting that abacavir may be less toxic to mitochondria.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!